It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Bioinformatics combines biological data, computational methods, and analytics to accelerate drug discovery. Our integrated approach can support target identification and evaluation, biomarker discovery, and translational decision-making ensuring insights lead to actionable drug discovery strategies.
We operate as a true extension of your team, delivering flexible, bespoke bioinformatics solutions that reduce risk and accelerate decision-making across the drug discovery pipeline.
Our bioinformatics experts transform complex, high-dimensional data into clear, actionable insight, integrating multimodal datasets to identify high-value targets, interpret experimental outcomes, and guide strategic direction.
Designed around your program, our end-to-end support spans early discovery through translational and clinical insight. Combined with our multidisciplinary expertise, collaborative approach, and proven track record, Sygnature Discovery is a trusted partner for advancing innovative therapies efficiently, confidently, and with scientific rigor.
Key Strengths
Integrated Drug Discovery
Our Bioinformatics team works across the entire drug discovery pipeline, from early target identification through to preclinical biomarker development. Using a robust, data‑driven approach, we support informed decision‑making, add scientific and strategic value, and help to de‑risk your development pipeline.
Deep Data
Our analysis pipelines are underpinned by a rich foundation of carefully curated data drawn from both internal research and trusted external sources. This comprehensive data landscape ensures robust, reliable, and continuously up-to-date support for discovery efforts across the pipeline.
NGS
We utilise cutting-edge next-generation sequencing (NGS) technologies in early discovery to deconvolute complex biological questions. These approaches provide deep molecular insight to support the assessment of target engagement, elucidate mechanisms of action, and identify potential off-target toxicities and resistance networks.
Lab-in-the-Loop
With continual feedforward processes embedded throughout our analytical pipelines, our scientists are consistently informed by high-quality, curated data. This integrated approach ensures insight is rapidly translated into action, enabling confident, timely, and accurate decision-making across projects.
AI Integration
The adoption of state-of-the-art, AI-driven approaches is ushering in a new era of discovery. Our scientists leverage advanced AI and Machine-Learning technologies to accelerate, optimize, and streamline discovery efforts across every stage of the drug development pipeline.
Biomarker Development
Bioinformatic approaches play a central role in biomarker discovery and evaluation during preclinical development. Our data-driven methodology supports the development of pharmacodynamic (PD), target-engagement (TE), efficacy, safety/toxicity, and exploratory biomarkers, enabling informed decision-making across the pipeline.
Typical Applications
Bioinformatics supports drug discovery across the full pipeline by turning complex data into actionable insight.
During target identification and validation, approaches such as comparative transcriptomics reveal disease-relevant genes and pathways by contrasting healthy and diseased states.
In early discovery, causal network analysis helps elucidate mechanism of action, linking targets to downstream biological effects.
At the IND stage, bioinformatics enables the discovery and validation of translational biomarkers to bridge preclinical and clinical data and support dose and patient selection strategies.
In the clinical stage, integrative analyses can uncover new disease drug relationships, enabling drug repositioning and maximizing therapeutic value.
Embedded within Sygnature’s multi-decade legacy of drug discovery, we ensure bioinformatics insights are scientifically rigorous and strategically aligned with real-world therapeutic development.
Why Choose Sygnature Discovery for Bioinformatics Support?
Partner with our Bioinformatics team to gain confident, insight‑led progression across the discovery and development pipeline.
We provide access to extensive curated biological datasets and a wealth of clinical trial data, integrated with trusted public and proprietary data sources to ensure gold-standard analyses are both comprehensive and credible.
Our bespoke LLM models accelerate and refine literature interrogation, enabling rapid, context‑aware evidence synthesis. This is reinforced by deep translational datasets that bridge preclinical and clinical understanding.
Crucially, our work is underpinned by a human‑in‑the‑loop model, combining advanced analytics with subject‑matter expertise to deliver scientifically rigorous, decision‑ready insights tailored to your program.
Built on Unmatched Biological Evidence
Expansive and curated dataset is a critical asset in drug development, reducing decision risk and improving confidence. Our diverse, high-quality data enhances target selection, biomarker validity, and patient stratification, accelerating development and increasing success rates.
Tatiana Rosado Rosenstock, Hiromitsu Ohzeki, Shohei Kumagai, Natsuno Suda, Colin Sambrook Smith Abstract Target identification (Target ID) is a foundational, multi-disciplinary method for identifying…
Sygnature Discovery is pleased to announce its new partner Elsevier, a global information and analytics…
News
FAQs
We offer end-to-end support for target and biomarker identification, including transcriptomics (bulk, single-cell, spatial RNAseq) and proteomics analysis, functional characterization and network biology, and variant calling. Our team integrates multi-omics data to guide strategic decisions across the discovery pipeline.
Yes. We routinely work with client-provided data and systems, ensuring seamless integration while maintaining scientific rigor and data security. Sygnature Discovery operates under ISO/IEC 27001-certified information security management systems, which guarantees that all client data is handled with the highest standards of confidentiality, integrity, and availability.
We use gold-standard tools like Qiagen IPA and Open Targets, we cross -reference findings with trusted databases (GTEx, TCGA, and Human Protein Atlas). We apply our automated workflows and expert reviews ensuring high-quality, reproducible review and sort Banner 1/2/3 levels on all Sgy pages content entry and update insights.
We work across oncology, immunology, metabolic disease, neuroscience, and rare diseases. Our team tailors bioinformatics strategies to the biological context and clinical relevance of each project.
Yes. We use semi-automated, human-in-the-loop pipelines alongside curated databases to assess target tractability, expression profiles, genetic associations, and disease linkage – helping you focus on the most promising candidates.
All our workflows are modular and customizable. Whether you need a one-off analysis or a fully embedded solution, we adapt our pipelines to your scientific goals, timelines, and data formats.
Yes. We provide follow-up consultations, data review sessions, and collaborative interpretation to ensure findings are actionable and aligned with your next steps.
Sygnature Discovery’s Bioinformatics team supports modality‑agnostic drug discovery, spanning small molecules, peptides, targeted protein degraders, antibody‑drug conjugates (ADCs), and biologics. By integrating omics, structural, and translational data, the team enables target identification, hit discovery, and candidate progression across diverse therapeutic modalities
AI and machine‑learning supported bioinformatics accelerate drug discovery by integrating and analysing large‑scale biological datasets to rapidly identify targets, prioritise hypotheses, and guide decision‑making. Embedded within an integrated digital drug discovery ecosystem, these approaches de‑risk programs and shorten timelines from target identification to clinical insight.
Our bioinformatics solutions help de‑risk drug discovery programs by integrating and analysing complex biological, translational, and experimental datasets. This enables robust target identification, validation, and data‑driven decision‑making. Embedded within a connected digital discovery ecosystem, bioinformatics reduces uncertainty, improves confidence, and accelerates progression from early discovery to IND.
At Sygnature Discovery, a bioinformatics‑driven, lab‑in‑the‑loop approach integrates computational analysis with experimental biology, chemistry, and translational science. Continuously feeding experimental data back into analysis through iterative workflows improves target validation, sharpens decision‑making, reduces risk, and accelerates progression toward high‑quality drug candidates. Early adoption of this process in drug development has been shown to maximise success.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Target Identification & Validation
Combining AI-driven insights, expert guidance, and rigorous lab validation to select and confirm targets for successful drug discovery.
Global chemistry expertise and tailored strategies combining medicinal, synthetic, and process capabilities advancing candidate-quality molecules with transparent collaboration.
Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.
